Skip to main content
Top

ESMO 2025: The DYNAMIC-III trial

Prof. Jeanne Tie explains why ctDNA-guided treatment de-escalation could be considered in certain patients with colon cancer despite the trial not meeting its primary endpoint. 

More from ESMO Congress 2025

Image Credits
Jeanne Tie/© Springer Medicine, Woman receiving an intravenous infusion/© FatCamera / Getty Images / iStock (symbolic image with model), Erica Mayer/© Springer Medicine, Christof Vulsteke/© Springer Medicine, DNA testing of blood - conceptual/© blindturtle / stock.adobe.com